News
NICE says yes to BeiGene's Brukinsa after Scottish nay
BeiGene's BTK inhibitor Brukinsa (zanubrutinib) has become the first drug in the class to be recommended for routine NHS use in England and Wales to treat Waldenström macroglobulinaemia (WM
